

Highlights in lung cancer in 2019



Kok Haw Jonathan Lim,¹ Sanjay Popat²

To cite: Lim KHJ, Popat S. Highlights in lung cancer in 2019. *ESMO Open* 2020;5:e000676. doi:10.1136/esmoopen-2020-000676

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

¹Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

²Lung Cancer Unit, The Royal Marsden NHS Foundation Trust, London, UK

Correspondence to

Dr Kok Haw Jonathan Lim; jonathan.lim@doctors.org.uk

[Click here to listen to the Podcast](#)

ABSTRACT

There have been significant advances in the treatment landscape of lung cancer in the recent few years. In this podcast, Jonathan Lim (a member of the European Society for Medical Oncology Young Oncologists Committee) interviews Professor Sanjay Popat (Professor of Thoracic Medical Oncology at The Royal Marsden Hospital, UK) on the highlights of lung cancer in 2019.

Professor Popat provides his perspective and contextualises how some of the key studies reported this year (including Check-Mate 227, IMpower110, KEYNOTE 042, FLAURA and CASPIAN) have been practice-changing. We also discuss the current utility and caveats of PD-L1 (programmed death-ligand 1) as a biomarker for immunotherapy with anti-PD1, and explore progress made in the clinical translation of circulating tumour DNA, circulating tumour cell and tumour

mutational burden. Finally, we talk about the recent hype on targeting KRAS in non-small cell lung cancer, and highlight what is on the horizon in 2020.

Funding KHJL is currently funded by the Wellcome Imperial 4i Clinical Research Fellowship.

Competing interests SP receives honoraria from Boehringer Ingelheim, AstraZeneca, Roche, Takeda and Chugai Pharma; and provides consulting or advisory role for Boehringer Ingelheim, AstraZeneca, Roche, Takeda, Novartis, Pfizer, Bristol-Myers Squibb, MSD, Guardant Health, AbbVie and EMD Serono.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.